Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage
Human Reproduction Update · 01.10.2024 · 30 (5) · 614-647
DOI: 10.1093/humupd/dmae020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Reproduction Update, online erschienen am 28.06.2024. Verfasst von Yican Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Ovary, Antineoplastic Agents. Die Arbeit wurde bisher 136-mal zitiert (Crossref) und nennt 370 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND Chemotherapy-associated ovarian damage (CAOD) is one of the most feared short- and long-term side effects of anticancer treatment in premenopausal women. Accumulating detailed data show that different chemotherapy regimens can lead to disturbance of ovarian hormone levels, reduced or lost fertility, and an increased risk of early menopause. Previous studies have often focused on the direct effects of chemotherapeutic drugs on ovarian follicles, such as direct DNA damage-mediated apoptotic death and primordial follicle burnout. Emerging evidence has revealed an imbalance in the ovarian microenvironment during chemotherapy. The ovarian microenvironment provides nutritional support and transportation of signals that stimulate the growth and development of follicles, ovulation, and corpus luteum formation. The close interaction between the ovarian microenvironment and follicles can determine ovarian function. Therefore, designing novel and precise strategies to manipulate the ovarian microenvironment may be a new strategy to protect ovarian function during chemotherapy. OBJECTIVE AND RATIONALE This review details the changes that occur in the ovarian microenvironment during chemotherapy and emphasizes the importance of developing new therapeutics that protect ovarian function by targeting the ovarian microenvironment during chemotherapy. SEARCH METHODS A comprehensive review of the literature was performed by searching PubMed up to April 2024. Search terms included ‘ovarian microenvironment’ (ovarian extracellular matrix, ovarian stromal cells, ovarian interstitial, ovarian blood vessels, ovarian lymphatic vessels, ovarian macrophages, ovarian lymphocytes, ovarian immune cytokines, ovarian oxidative stress, ovarian reactive oxygen species, ovarian senescence cells, ovarian senescence-associated secretory phenotypes, ovarian oogonial stem cells, ovarian stem cells), terms related to ovarian function (reproductive health, fertility, infertility, fecundity, ovarian reserve, ovarian function, menopause, decreased ovarian reserve, premature ovarian insufficiency/failure), and terms related to chemotherapy (cyclophosphamide, lfosfamide, chlormethine, chlorambucil, busulfan, melphalan, procarbazine, cisplatin, doxorubicin, carboplatin, taxane, paclitaxel, docetaxel, 5-fluorouraci, vincristine, methotrexate, dactinomycin, bleomycin, mercaptopurine). OUTCOMES The ovarian microenvironment shows great changes during chemotherapy, inducing extracellular matrix deposition and stromal fibrosis, angiogenesis disorders, immune microenvironment disturbance, oxidative stress imbalances, ovarian stem cell exhaustion, and cell senescence, thereby lowering the quantity and quality of ovarian follicles. Several methods targeting the ovarian microenvironment have been adopted to prevent and treat CAOD, such as stem cell therapy and the use of free radical scavengers, senolytherapies, immunomodulators, and proangiogenic factors. WIDER IMPLICATIONS Ovarian function is determined by its ‘seeds’ (follicles) and ‘soil’ (ovarian microenvironment). The ovarian microenvironment has been reported to play a vital role in CAOD and targeting the ovarian microenvironment may present potential therapeutic approaches for CAOD. However, the relation between the ovarian microenvironment, its regulatory networks, and CAOD needs to be further studied. A better understanding of these issues could be helpful in explaining the pathogenesis of CAOD and creating innovative strategies for counteracting the effects exerted on ovarian function. Our aim is that this narrative review of CAOD will stimulate more research in this important field. REGISTRATION NUMBER Not applicable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
- National Clinical Research Center for Obstetrical and Gynecological Diseases, Wuhan, Hubei, China.
- Key Laboratory of Cancer Invasion and Metastasis, Ministry of Education, Wuhan, Hubei, China.
- Department of Obstetrics and Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, China.
ORCID-Profile: Jun Dai, Meng Wu, Shixuan Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Guo, Y., Xue, L., Tang, W., Xiong, J., Chen, D., Dai, Y., Wu, C., Wei, S., Dai, J., Wu, M., & Wang, S. (2024). Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage. Human Reproduction Update, 30(5), 614-647. https://doi.org/10.1093/humupd/dmae020
Vancouver
Guo Y, Xue L, Tang W, Xiong J, Chen D, Dai Y, et al. Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage. Human Reproduction Update. 2024;30(5):614-647. doi:10.1093/humupd/dmae020
BibTeX
@article{Guo2024,
author = {Guo, Yican and Xue, Liru and Tang, Weicheng and Xiong, Jiaqiang and Chen, Dan and Dai, Yun and Wu, Chuqing and Wei, Simin and Dai, Jun and Wu, Meng and Wang, Shixuan},
title = {Ovarian microenvironment: challenges and opportunities in protecting against chemotherapy-associated ovarian damage},
journal = {Human Reproduction Update},
year = {2024},
volume = {30},
number = {5},
pages = {614--647},
doi = {10.1093/humupd/dmae020}
}
EUVIMED